首页> 外国专利> Methods for evaluating tissue morphogenesis and activity

Methods for evaluating tissue morphogenesis and activity

机译:评价组织形态发生和活性的方法

摘要

The present invention is based on the discovery that a true tissue morphogen such as OP-1 provided systemically, alone in its mature dimeric form, or as part of a soluble complex, can induce new replacement tissue regeneration at a localized, permissive defect site distal to the site of administration. Specifically, systemically administered protein is sufficient to induce formation of new functional replacement tissue, sufficient to repair a local defect in a tissue, including skeletal or orthopedic tissues, liver, pancreas, lung, cardiac, renal, uterine, intestinal, gastrointestinal tissue. (As used herein, “orthopedic” or “skeletal” or “joint” or “chondrogenic” tissue is understood to encompass the skeletal and skeletal joint tissues: bone, cartilage, tendon, ligament, and synovial membrane tissues.) It further has been discovered that a single injection of morphogenic protein is sufficient to induce the desired biological effect, and that administration is not time-sensitive, provided mesenchymal progenitor cells are accessible to the defect site. That is, morphogenic protein can be provided to an individual having a local permissive defect site, shortly after creation of the defect, or at some significant time later, including, without limitation, after the initiation of fibrotic tissue formation. Thus, means now are available for enhancing restoration of tissue function and/or repair or regeneration of functional replacement tissue by systemically administering morphogenic protein, at times significantly after creation of the defect. The methods and formulations can be used to repair local defects without requiring surgical intervention; can enhance the rate and quality of new replacement tissue formation, particularly in compromised individuals with a reduced capacity to undergo spontaneous healing, and can be used to induce new tissue formation even after the initiation of fibrosis at the defect site. This discovery is disclosed in copending U.S. Patent Application filed on even date herewith, the disclosure of which is incorporated herein by reference.
机译:本发明基于以下发现:以其成熟的二聚体形式单独或作为可溶性复合物的一部分系统地提供的真实组织形态发生剂,例如OP-1,可以在远端的局部允许的缺损部位诱导新的替代组织再生。到管理站点。具体地,全身施用的蛋白质足以诱导新的功能替代组织的形成,足以修复组织中的局部缺陷,所述组织包括骨骼或整形外科组织,肝脏,胰腺,肺,心脏,肾脏,子宫,肠,胃肠组织。 (如本文所用,“整形外科”或“骨骼”或“关节”或“软骨形成”组织应理解为包括骨骼和骨骼关节组织:骨骼,软骨,肌腱,韧带和滑膜组织。)他发现,一次注射的形态发生蛋白足以诱导所需的生物学效应,并且只要间充质祖细胞可进入缺损部位,给药就不会对时间敏感。就是说,可以在缺陷产生后不久或在以后的一些重要时间(包括但不限于在纤维化组织形成开始之后)向具有局部容许缺陷位点的个体提供形态发生蛋白。因此,现在可利用通过全身施用形态发生蛋白来增强组织功能的恢复和/或功能替代组织的修复或再生的方法,所述方法有时在产生缺陷后有时显着地进行。该方法和制剂可用于修复局部缺陷,而无需外科手术干预。可以提高新的替代组织形成的速度和质量,特别是在受损的个体中,其自发愈合能力降低,甚至可以在缺损部位开始纤维化后也可用于诱导新的组织形成。该发现在与此同时提交的共同待审的美国专利申请中公开,其公开内容通过引用结合在此。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号